Short answer:
Rifampin reduces tigecycline exposure (≈ 40–50 % lower AUC and Cmax) by inducing hepatic enzymes and drug transporters that accelerate tigecycline clearance. The FDA‑approved label does not recommend a formal dose change for tigecycline when given with rifampin; instead, clinicians are advised to monitor clinical response and consider dose adjustments only on an individual‑patient basis.
---
What’s actually happening?
| Parameter | Tigecycline alone | Tigecycline + Rifampin |
|-----------|-------------------|------------------------|
| AUC (exposure) | Normal | ↓ ~ 40–50 % |
| Cmax (peak) | Normal | ↓ ~ 20–30 % |
| Clearance (CL) | Baseline | ↑ ↑ (due to enzyme/transport induction) |
| Half‑life | ~ 29 h | Shortened (≈ 20–25 h) |
Mechanism
- Rifampin is a strong inducer of CYP3A4, UGTs, and especially the drug transporter P‑glycoprotein (P‑gp) and multidrug resistance‑associated proteins (MRPs).
- Tigecycline, although not primarily metabolized by CYP enzymes, is a substrate for these transporters, so rifampin’s induction speeds up its hepatic uptake, biliary excretion, and renal clearance.
- The net effect is a lower steady‑state concentration of tigecycline in the bloodstream.
---
Practical dosing guidance
| Situation | What to do |
|-----------|------------|
| Routine use of tigecycline (100 mg loading, 50 mg q12 h) | Keep the standard regimen; no formal dose increase is recommended by the FDA. |
| Severe infection or inadequate response | Consider doubling the maintenance dose to 100 mg q12 h or extending the infusion time, but only after weighing the risk of toxicity (especially nausea, vomiting, or mild liver enzyme elevations). |
| Monitoring | Check for clinical improvement (fever resolution, decreasing inflammatory markers). If the patient remains infected or shows poor response, reevaluate the dose. |
| Other drug interactions | Rifampin can also lower serum concentrations of other drugs that are P‑gp substrates (e.g., fluoroquinolones, vancomycin). Adjust accordingly. |
Key take‑away: Rifampin significantly lowers tigecycline levels, but the label does not mandate a dose change. In practice, keep the standard dose unless the patient is not responding adequately; then consider a higher dose or a longer infusion, always with close clinical monitoring.